Literature DB >> 3019362

Cytomegalovirus viremia increases with progressive immune deficiency in patients infected with HTLV-III.

M Fiala, L A Cone, C M Chang, E S Mocarski.   

Abstract

Cytomegalovirus (CMV) viremia was studied in 15 homosexual patients [two healthy, nine with the acquired immune deficiency syndrome (AIDS), five with the AIDS-related complex (ARC)], in one patient with transfusion-related AIDS, and in four individuals with cancer or connective tissue disorders. While CMV viremia was absent in the latter patients, in the healthy homosexuals, and in three stable ARC patients, it was present in clinically-deteriorating ARC patients and in all nine AIDS patients. Some CMV isolates caused limited proliferation of fibroblasts in the culture medium. The rapidity and ease of CMV isolation from leukocytes of patients at different stages of infection with human T-lymphocytotropic virus type III (HTLV-III) indicate that the CMV titer in leukocytes increases as immune deficiency worsens. In ARC patients CMV viremia may be predictive of clinical complications in the next 3 months. In AIDS patients CMV viremia at high titer was an unfavorable prognostic sign.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019362     DOI: 10.1089/aid.1.1986.2.175

Source DB:  PubMed          Journal:  AIDS Res        ISSN: 0737-6006


  22 in total

1.  Colocalisation of human immunodeficiency virus and human cytomegalovirus infection in brain autopsy tissue from AIDS patients.

Authors:  I M Balluz; M A Farrell; E Kay; M J Staunton; J N Keating; O Sheils; S L Cosby; M J Mabruk; B J Sheahan; G J Atkins
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

2.  Absence of interaction between porcine endogenous retrovirus and porcine cytomegalovirus in pig-to-baboon renal xenotransplantation in vivo.

Authors:  Jay A Fishman; David H Sachs; Kazuhiko Yamada; Robert A Wilkinson
Journal:  Xenotransplantation       Date:  2018-04-06       Impact factor: 3.907

3.  A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins.

Authors:  P Ghazal; J Young; E Giulietti; C DeMattei; J Garcia; R Gaynor; R M Stenberg; J A Nelson
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.

Authors:  M A Subler; D W Martin; S Deb
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

5.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients.

Authors:  R L Saltzman; M R Quirk; M C Jordan
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Modulation of T-cell activation through protein kinase C- or A-dependent signalling pathways synergistically increases human immunodeficiency virus long terminal repeat induction by cytomegalovirus immediate-early proteins.

Authors:  C V Paya; J L Virelizier; S Michelson
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

9.  Cytomegalovirus infection of the brain in AIDS: a clinicopathological study.

Authors:  U Setinek; E Wondrusch; K Jellinger; A Steuer; M Drlicek; W Grisold; F Lintner
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  TAR-independent transactivation of the murine cytomegalovirus major immediate-early promoter by the Tat protein.

Authors:  Y S Kim; R Risser
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.